ESMO Gynae 2025 | RUBY: assessing secondary endpoints of dostarlimab in endometrial cancer

So the RUBY trial, this is the second interim analysis and in the larger context, an incredibly exciting time in the treatment of uterine cancer as we have a deeper understanding of molecular targets and specifically how that guides new treatment options for patients. So this trial in particular uses an immune checkpoint inhibitor dostarlimab in combination with standard treatment. And this second interim analysis, which was performed in the fall of 2023, gives us sort of additional three-year follow-up of the original study that found a significant benefit for patients with the addition of this immune checkpoint inhibitor dostarlimab with Taxol and carboplatin chemotherapy. So I’m specifically in this particular abstract, we’re focusing on a couple of secondary endpoints, namely looking at how age impacts response, because as you may or may not know, a lot of our patients with uterine cancer are older, and the cutoff we’ve used in this study is greater than or less than 70 years of age. And then the second nuance with this particular abstract is the time to next subsequent treatment and then time to the sort of the first treatment after the original Taxol carboplatin and dostarlimab for those patients in whom the cancer recurred and then the time to the subsequent or second treatment for those patients who had a treatment or response and then their cancer came back again. These parameters as we can discuss are also another way to really look at not only the original impact therapy, but how that affects the patient’s journey with her cancer as a result of these treatments.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.